This trial is evaluating whether 68Ga-HBED-CC-PSMA PET/CT will improve 3 primary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 7 days.
This trial requires 1500 total participants across 1 different treatment group
This trial involves a single treatment. 68Ga-HBED-CC-PSMA PET/CT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"While radiation therapy and adjuvant hormonal treatment are often used in the initial management of prostate cancer, newer medications (such as abiraterone and enzalutamide) demonstrate improved efficacy compared to standard care (through androgen deprivation or bisphosphonate) in certain cohorts. When offered to older men, the benefit of abiraterone is greatest among men with metastatic disease. Abiraterone may be considered in men with low-risk localized prostate cancer and favorable pathology. Combination treatments of hormonal and abiraterone (CHAMPS) may allow for selection of optimal treatment in men who cannot receive either agent alone." - Anonymous Online Contributor
"The question of cure can be answered with high certainty only for a small subset of patients. There are many other aspects of management of prostate cancer." - Anonymous Online Contributor
"Most prostate cancer will be diagnosed in men younger than 60 years old and those over 70 years older. Age and sex are risk factors for prostate cancer. Many men with prostate cancer are diagnosed after their screening PSA is performed, which demonstrates how important it is for men to be screened for prostate cancer as soon as they are diagnosed with some prostate cancer." - Anonymous Online Contributor
"In particular, patients with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) are at higher risk for depression, fatigue and anorexia compared to men that have not developed cancer. Men are at risk for developing prostate cancer as a means of mitigating their sense of isolation. These early life factors should prompt earlier diagnosis and increased screening of cancer in men because the signs of prostate cancer can be missed." - Anonymous Online Contributor
"Prostate cancer is a disease of unknown cause, but multiple pathways trigger the transformation of normal cells into cancerous ones. There is no conclusive proof of a single, specific cause for prostate cancer, as the disease is genetically and environmentally influenced." - Anonymous Online Contributor
"Recent findings indicated that [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is a cancer of the exocrine glands. Symptoms of high urgency, dysuria, excessive frequency of bowel movements, and pain with intercourse are the main presenting symptoms of prostate cancer. However, symptoms such as the urgency, dysuria, and frequency may be underestimated. Diagnosis and treatment of prostate cancer have been improved. Awareness among men and their physicians may lead to early diagnosis of prostate cancer and to improved treatment outcome." - Anonymous Online Contributor
"PET demonstrated no significant change to plan between 68Ga-PET and 99mTc-PSA. PET did show significant changes between 68Ga-PET and 68Ga-Tc-PSA. 68Ga-PET can be used as a supplementary diagnostic tool as a method to assess the degree of tumour burden. The imaging findings confirmed metastatic behaviour of 68Ga-PET or 68Ga-Tc-PSA. PET did not predict the size of the primary tumour. However, PET scans may play a significant role in detecting micrometastatic disease (which would not be detected by biochemical markers)." - Anonymous Online Contributor
"This article provides an overview of the recent research on prostate cancer, including articles that report the advancement of prostate cancer prevention or chemotherapies that may have therapeutic effects in treating prostate cancer. Furthermore, the article also serves as a reminder of the limitations of the clinical trials that are the basis for the advancement of knowledge of prostate cancer and the improvement of treatment of prostate cancers." - Anonymous Online Contributor
"With our findings, we may have found a candidate to add in the therapeutic toolbox for LUTS. We have therefore undertaken a large multicenter trial with the focus on further defining the therapeutic efficacy of 68Ga-HBED-cc-PSMA pet PET/CT in patients with a clinical suspicion of LUTS caused by bladder neck dysfunction, and potentially also of (bladder neck) prostatitis." - Anonymous Online Contributor
"It could not be determined the effectiveness of 68Ga-HEDEC-CCPSA with concurrent chemotherapy or CT alone, to define the clinical effectiveness of PETCT. Findings from a recent study of this retrospective study, therefore, are not indicative. It could not be defined the effectiveness of 68Ga-HEDEC-CCPSA in combination with other treatments. Findings from a recent study of this retrospective study, therefore, are not indicative. In terms of the prognosis of the patients, the results of this study are not indicative." - Anonymous Online Contributor
"The metastasis-free survival rate of prostate cancer patients is influenced by many variables, such as tumour size, metastatic involvement, grade of differentiation, PSA concentration and treatment. Survival was highest for patients with the lowest PSA-levels." - Anonymous Online Contributor
"Recent findings of meta-analysis of the current data are limited by their small numbers due to the availability of only one comparative investigation. However, our data suggest that 68Ga is effective regarding patient survival when used in conjunction with a low dose of the chelate generator CC-PSMA." - Anonymous Online Contributor